Peer-influenced content. Sources you trust. No registration required. This is HCN.

Annals of Internal MedicineCannabis-Based Products for Chronic Pain

The review, which we covered previously, concluded that “oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios may be associated with short-term improvements in chronic pain and increased risk for dizziness and sedation.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form